Free Trial
NASDAQ:CNTX

Context Therapeutics (CNTX) Stock Price, News & Analysis

Context Therapeutics logo
$1.21 +0.12 (+11.01%)
As of 01/8/2025 04:00 PM Eastern

About Context Therapeutics Stock (NASDAQ:CNTX)

Key Stats

Today's Range
$1.08
$1.25
50-Day Range
$0.98
$2.27
52-Week Range
$0.89
$2.75
Volume
783,242 shs
Average Volume
342,874 shs
Market Capitalization
$90.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.33
Consensus Rating
Buy

Company Overview

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Context Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
50th Percentile Overall Score

CNTX MarketRank™: 

Context Therapeutics scored higher than 50% of companies evaluated by MarketBeat, and ranked 646th out of 956 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Context Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Context Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Context Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Context Therapeutics are expected to grow in the coming year, from ($0.51) to ($0.31) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Context Therapeutics is -1.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Context Therapeutics is -1.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Context Therapeutics has a P/B Ratio of 1.64. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.67% of the float of Context Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Context Therapeutics has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Context Therapeutics has recently increased by 22.86%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Context Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Context Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.67% of the float of Context Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Context Therapeutics has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Context Therapeutics has recently increased by 22.86%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Context Therapeutics has a news sentiment score of 1.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.98 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for Context Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    3 people have searched for CNTX on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • MarketBeat Follows

    Only 3 people have added Context Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Context Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.04% of the stock of Context Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 14.03% of the stock of Context Therapeutics is held by institutions.

  • Read more about Context Therapeutics' insider trading history.
Receive CNTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Context Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CNTX Stock News Headlines

Combine the QQQ, IWM and SPY in one trade
If you’ve been investing in the major indexes for the last 20 years, you may need a new strategy. Because the Dow Jones has returned just 349%... The Russell 2000 has returned just 397%... And the S&P 500 has returned just 450%. And although I can’t guarantee results or against losses… I want to tell you about my “2-Click Trade” that has encapsulated more than the return of ALL THREE OF THOSE INDEXES COMBINED… Plus, it targets multiple overnight payouts in a month with 84.3% accuracy! While I cannot promise future returns or against losses…
Context Therapeutics (NASDAQ: CNTX)
Context Therapeutics Secures Funding for Cancer Therapy Pipeline
Context Therapeutics: Strategic Developments and Financial Outlook
See More Headlines

CNTX Stock Analysis - Frequently Asked Questions

Context Therapeutics' stock was trading at $1.05 on January 1st, 2025. Since then, CNTX shares have increased by 15.2% and is now trading at $1.21.
View the best growth stocks for 2025 here
.

Context Therapeutics Inc. (NASDAQ:CNTX) announced its earnings results on Wednesday, November, 6th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.11) by $0.11.

Context Therapeutics (CNTX) raised $25 million in an initial public offering on Wednesday, October 20th 2021. The company issued 5,000,000 shares at $5.00 per share.

Shares of CNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Context Therapeutics investors own include NVIDIA (NVDA), Sangamo Therapeutics (SGMO), Arista Networks (ANET), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE) and Celestica (CLS).

Company Calendar

Last Earnings
11/06/2024
Today
1/09/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CNTX
Fax
N/A
Employees
7
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.33
High Stock Price Target
$10.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+423.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-23,960,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.74 per share

Miscellaneous

Free Float
72,718,000
Market Cap
$90.75 million
Optionable
Not Optionable
Beta
2.10
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

This page (NASDAQ:CNTX) was last updated on 1/9/2025 by MarketBeat.com Staff
From Our Partners